# A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis

> **NCT05704361** · PHASE1 · RECRUITING · sponsor: **Hoffmann-La Roche** · enrollment: 129 (estimated)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** RO7121932 IV
- **DRUG:** RO7121932 SC

## Key facts

- **NCT ID:** NCT05704361
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-08-11
- **Primary completion:** 2027-07-08
- **Final completion:** 2027-07-08
- **Target enrollment:** 129 (ESTIMATED)
- **Last updated:** 2026-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05704361

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05704361, "A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05704361. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*